Zomedica Expands Market Opportunity For Truforma Diagnostic Platform With Launch Of First-And-Only Point Of Care eACTH Assay For Diagnosis, Management Of Cushing's Disease In Horses
Portfolio Pulse from Benzinga Newsdesk
Zomedica has launched the first and only point of care eACTH assay for the diagnosis and management of Cushing's disease in horses, expanding the market opportunity for its Truforma Diagnostic Platform.

September 14, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zomedica's launch of a unique eACTH assay for Cushing's disease in horses expands the market for its Truforma Diagnostic Platform, potentially boosting revenues.
The launch of a unique product that expands the market for a company's existing platform typically leads to increased sales and revenues. Given that this is the first and only point of care eACTH assay for Cushing's disease in horses, it could give Zomedica a competitive edge in the market, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100